D-ormaplatin (previously called tetraplatin) produced dose-related renal papillary necrosis when given intravenously to Fischer-344 rats at doses of 2, 4, and 9 mg/kg. The lesions were most severe at 4 days postdosing and had repaired by day 9 in the 2-and 4-mg/kg dose groups. Blood urea nitrogen and the N-acetyl-β-glucosaminidase (NAG): creatinine ratio were slightly elevated at day 4 while creatinine clearance was decreased. Body weight was reduced in a dose-related manner while kidney weights increased. Total protein excretion in male and female rats was elevated at day 4 postdosing. The evaluation of urinary proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) revealed an increase, primarily in high molecular weight proteins at 4 days postdosing, indicating an increase in glomerular filtration of albumin and transferrin. The morphologic appearance of the glomeruli was normal by light microscopy. At day 4 postdosing, α1-microglobulin was elevated. This correlated with an increase in the NAG: creatinine ratio also seen at this time and the morphologic appearance of the kidney, indicating that the proximal tubules were affected but were not a major site of toxicity. Although the change in urinary proteins occurred at the same time as morphologic alterations in the renal papilla, these findings were not considered to be related. SDS-PAGE provided a useful method for detecting and localizing renal toxicity when used in conjunction with morphologic and clinical chemistry methods.
1. Anderson WK, Quagliato DA, Haugwitz RD, Narayanan VL, and Wolpert-DeFilippes MK (1986). Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2-diaminocyclohexane.Cancer Treat. Rep.70(8): 997–1002.
2.
2. Bach PH and Bridges JW (1985). Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 1.CRC Crit. Rev. Toxicol.15(3): 217–329.
3.
3. Bach PH and Bridges JW (1985). Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 2.CRC Crit. Rev. Toxicol.15(4): 331–441.
4.
4. Bernard A and Lauwerys RR (1991). Proteinuria: Changes and mechanisms in toxic nephropathies.Toxicology21(5): 373–405.
5.
5. Biotrol USA Incorporated (1989). Total Protein Method. Biotrol Urine Proteins Reagent Kit insert #TO1217US9991. Biotrol USA Incorporated, Exton, Pennsylvania 19341.
6.
6. Bovee KC (1986). Renal function and laboratory evaluation.Toxicol. Pathol.14(1): 26–35.
7.
7. Carlton WW and Engelhardt JA (1989). Experimental renal papillary necrosis in the Syrian hamster.Food Chem. Toxicol.27(5): 331–340.
8.
8. Caulfield JP and Farquhar MG (1978). Loss of anionic sites from the glomerular basement membrane in aminonucleoside nephrosis.Lab. Invest.39(5): 505.
9.
9. Champion de C, Hewitson T, Birchall I, and Kincaid-Smith P (1990). Caffeine potentiates the nephrotoxicity of mefenamic acid on the rat renal papilla.Am. J. Nephrol.10(4): 311–315.
10.
10. Chavers BM and Vernier RL (1986). Proteinuria and enzymuria.Sem. Nephrol.6(4): 371–388.
11.
11. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, Trump BF, and Chase DH (1981). Cis-diamminedichlorplatinum-induced acute renal failure in the rat.Kidney Int.21: 54–64.
12.
12. Colome NE, Solans R, Espinach J, Delgadillo J, and Fonallosa V (1991). Renal papillary necrosis induced by flurbiprofen (letter). DICP Ann. Pharmacother.25(7–8): 870–871.
13.
13. Dobyan DC, Levi J, Jacobs C, Kosek J, and Weiner MW (1980). Mechanism of cis -platinum nephrotoxicity: II. Morphologic observations.J. Pharmacol. Exp. Ther.213(3): 551–556.
14.
14. Elliott G, Whited BA, Purmalis A, Davis JP, Field SO, Lancaster C, and Robert A (1986). Effect of 16,16-dimethyl PGE2 on renal papillary necrosis and gastrointestinal ulcerations (gastric, duodenal, intestinal) produced in rats by mefenamic acid.Life Sci.39(5): 423–432.
15.
15. Goren MP, Wright RK, and Horowitz ME (1986). Cumulative renal tubular damage associated with cisplatin nephrotoxicity.Cancer Chemother. Pharmacol.18: 69–73.
16.
16. Gregg NJ, Courtauld EA, and Bach PH (1990). High resolution light microscopic morphological and microvascular changes in an acutely induced renal papillary necrosis. Toxicol. Pathol.18(1, Pt. 1): 47–55.
17.
17. Halman J, Miller J, Fowler JSL, and Price RG (1986). Renal toxicity of propyleneimine: Assessment by noninvasive techniques in the rat.Toxicology41: 43–59.
18.
18. Henry MA and Tange JD (1987). Lesions of the renal papilla induced by paracetamol.J. Pathol.151(1): 11–19.
19.
19. Jappe MA (1986). Creatinine clearance method.Physiol. Chem.10: 391.
20.
20. Kanwar YS, Linker A, and Gist Farquhar M (1980). Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion.J. Cell Biol.86: 688–693.
21.
21. Kolaja GJ, VanderMeer DA, Packwood WH, and Satoh PS (1992). The use of SDS PAGE to detect renal damage in Sprague-Dawley rats treated with gentamicin sulfate.Toxicol. Pathol.20: 603–607.
22.
22. Lai FM, Lai KN, and Chong YW (1987). Papillary necrosis associated with rifampicin therapy.Aust. N.Z. J. Med.17(1): 68–70.
23.
23. Lenz SD and Charlton WW (1990). Diphenylamine-induced renal papillary necrosis and necrosis of the pars recta in laboratory rodents.Vet. Pathol.27(3): 171–178.
24.
24. Matsudaira PD and Burgess DR (1978). SDS microslab linear gradient polyacrylamide gel electrophoresis.Anal. Biochem.87: 386–396.
25.
25. Morioka T, Sugano H, Matsui K, Kagami S, Shimizu F, and Oite T (1988). The electrophoretic pattern of urinary protein in in situ immune complex glomerulonephritis.Nephron50: 116–120.
26.
26. Mynderse LA, Hassell JR, Kleinman HK, Martin GR, and Martinez-Hernandez A (1983). Loss of heparan sulfate proteoglycan from glomerular basement membrane of nephrotic rats.Lab. Invest.48(3): 292.
27.
27. Powell CJ, Grasso P, Ioannides C, Wilson J, and Bridges JW (1991). Haloalkylamine-induced renal papillary necrosis: A histopathological study of structure-activity relationships.Int. J. Exp. Pathol.72(6): 631–646.
28.
28. Sabatini S (1988). Analgesic-induced papillary necrosis.Semin. Nephrol.8(1): 41–54.
29.
29. Safirstein R, Miller P, Dikman S, Lyman N, and Shapiro C (1981). Cisplatin nephrotoxicity in rats: Defect in papillary hypertonicity.Am. J. Physiol.241: F175–F185.
30.
30. Scherberich JE, Fischer P, Bigalke A, Stangl P, Wolf GB, Haimerl M, and Schoeppe W (1989). Routine diagnosis with PhastSystem compared to conventional electrophoresis: Automated sodium dodecyl sulfate-polyacrylamide gel electrophoresis, silver staining and Western blotting of urinary proteins.Electrophoresis10: 58–62.
31.
31. Smith JH, Smith MA, Litterst CL, Copley MP, Uozumi J, and Boyd MR (1988). Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer-344 rat.Fund. Appl. Toxicol.10: 45–61.
32.
32. Smith MA, Smith JH, Litterst CL, Copley MP, Uozumi J, and Boyd MR (1988). In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer-344 rat.Fund. Appl. Toxicol.10: 62–72.
33.
33. Stierle HE, Oser B, and Boesken WH (1990). Improved classification of proteinuria by semiautomated ultrathin SDS polyacrylamide gel electrophoresis.Clin. Nephrol.33(4): 168–173.
34.
34. Stonard MD, Gore CW, Oliver GJA, and Smith IK (1987). Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.Fund. Appl. Toxicol.9: 339–351.
35.
35. Weber MH (1988). Urinary protein analysis.J. Chromatogr.429: 315–344.
36.
36. Winnefeld DAK and Braunlich H (1988). Nephrotoxicity and pharmacokinetics of cisplatinum in young and adult rats.Biomed. Biochim. Acta47(8): 791–797.
